High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.
We conducted a double-blind trial of high-dose parenteral 6-methylprednisolone (MP) and placebo on 23 patients with acute MS. After the double-blind trial, the patients were given corticosteroids in gradually decreasing doses. The frequency of improvement was significantly higher and the bout duration significantly lower in the MP group than in the placebo group. The first signs of improvement (3 to 6 days after starting MP) were associated with a marked decrease in the rate of CNS IgG synthesis, but IgG CSF oligoclonal bands did not change. CNS IgG production slowly returned toward baseline despite progressive clinical improvement.
D000328:Adult; D000368:Aged; D000418:Albumins / Q000134:cerebrospinal fluid / Q000276:immunology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000134:cerebrospinal fluid / Q000276:immunology; D007263:Infusions, Parenteral; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation; D012709:Serum Albumin / Q000276:immunology; D013997:Time Factors
D000418:Albumins; D007074:Immunoglobulin G; D012709:Serum Albumin; D011241:Prednisone; D008775:Methylprednisolone